Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a…
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression…
